Vitamin B1 Deficiency and Vision Loss in GLP-1 Users: What the New Evidence Shows

Alert: Vitamin B1 deficiency can become a serious neurological risk for a small, vulnerable subset of people taking <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 medicines—especially when treatment is accompanied by persistent vomiting, severe appetite suppression, rapid weight loss, or very low food intake. The resulting thiamine deficiency can cause Wernicke encephalopathy, a medical emergency that may involve confusion, loss of coordination, abnormal eye movements, and, in uncommon cases, optic-nerve injury or vision loss.

That warning needs context. The evidence does not show that every person taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 drug faces a meaningful risk of blindness. It also does not prove that these medicines directly destroy vitamin B1. Instead, the strongest current hypothesis is indirect: appetite suppression and gastrointestinal side effects may reduce food intake long enough to deplete thiamine in susceptible patients.

A second issue is receiving major attention. Semaglutide and other GLP-1 medicines are being studied in relation to nonarteritic anterior ischemic optic neuropathy, or NAION. NAION is a rare optic-nerve disorder that usually causes sudden, painless vision loss in one eye. It is not the same condition as vitamin B1 deficiency or Wernicke encephalopathy. Separating these pathways matters because their symptoms, evidence, and clinical questions differ.

The practical conclusion is straightforward: persistent vomiting, inability to eat, confusion, abnormal eye movements, severe imbalance, or sudden vision loss should not be dismissed as an ordinary medication side effect. These symptoms require prompt medical assessment.

What the new 2026 evidence actually found

The most direct evidence comes from a pharmacovigilance study published in Clinical Nutrition in February 2026. Pharmacovigilance is the monitoring of suspected medicine-related harms after products reach wider use. Researchers examined reports in the U.S. Food and Drug Administration Adverse Event Reporting System and combined those data with a review of published medical literature. They identified 15 cases of Wernicke encephalopathy reported in people receiving GLP-1 receptor agonist treatment. Eight cases involved semaglutide and six involved tirzepatide; one involved another GLP-1 medicine. Fourteen of the 15 reports occurred during 2023 or 2024, a period when use of these medicines expanded rapidly.

Thirteen of the 15 patients had gastrointestinal or nutritional features that could plausibly reduce thiamine intake. These included vomiting, appetite loss, weight loss, or malnutrition. Eleven had some of the classic neurological features of Wernicke encephalopathy, but only two had the complete textbook triad of altered mental status, gait or coordination problems, and eye-movement abnormalities. Seven of 11 patients with follow-up information had long-term neurological sequelae, meaning lasting effects after the acute illness.

The authors also found disproportionate reporting compared with other medicines. The reporting odds ratio was 2.35, with a 95% confidence interval of 1.38 to 4.01. This pattern was strong enough to justify a safety signal. It does not mean that 2.35% of GLP-1 users develop the condition, and it cannot establish how often the condition occurs. Spontaneous reporting systems do not include every treated patient, and reports may be affected by publicity, missing information, duplicate submissions, and uncertainty about diagnosis. The study is therefore a signal-detection analysis, not a population-incidence study. The full study is indexed in PubMed.

A second review, published in September 2026, looked specifically at semaglutide use for obesity. The investigators found six published case reports that met their criteria. Every patient had prolonged gastrointestinal symptoms and substantial weight loss before neurological deterioration. Common findings included altered mental status and abnormal eye movements. Several patients experienced poor outcomes, including progression to Korsakoff syndrome or death. Because all six cases were case reports, the review cannot determine whether semaglutide caused the condition, how common it is, or whether the same risk applies across all GLP-1 medicines. The September 2026 systematic review is available through PubMed.

Together, these studies support vigilance rather than panic. They identify a plausible nutritional pathway and show that delayed diagnosis can have lasting consequences. They do not support the claim that millions of GLP-1 users are progressing toward blindness.

How vitamin B1 deficiency can affect the brain and eyes

Vitamin B1, also called thiamine, is required for energy metabolism. Nerve cells depend heavily on glucose and oxygen, so tissues with high metabolic demand are particularly vulnerable when thiamine-dependent pathways fail. The brain, peripheral nerves, heart, and muscles can all be affected.

Wernicke encephalopathy is the acute neurological syndrome most closely associated with severe thiamine deficiency. It is classically described by three findings: confusion or altered mental status, problems with coordination or walking, and abnormalities of eye movement. In practice, many patients do not show all three. Waiting for the complete triad can delay recognition.

Eye findings may include nystagmus, double vision, weakness of the eye muscles, or difficulty coordinating gaze. In rare cases, thiamine deficiency can involve the optic nerves and cause reduced visual acuity or visual-field abnormalities. Vision loss related to nutritional optic neuropathy is biologically different from NAION. The former reflects metabolic injury related to nutrient deficiency; the latter reflects impaired blood flow to the optic nerve.

Severe or prolonged deficiency may also progress to Korsakoff syndrome, a chronic disorder involving memory impairment and difficulty forming new memories. Some patients recover substantially after urgent treatment, while others retain permanent neurological damage. That is why persistent vomiting and severe dietary restriction matter even before obvious neurological symptoms appear.

Thiamine status can be difficult to assess with a single laboratory result. Blood testing may be unavailable, delayed, or affected by recent supplementation. Clinical judgment is important when the history strongly suggests prolonged poor intake or vomiting. Treatment decisions belong to clinicians, particularly because suspected Wernicke encephalopathy is an emergency and may require parenteral therapy rather than relying on routine dietary intake.

Why GLP-1 treatment may create an indirect B1 risk

GLP-1 receptor agonists reduce appetite and slow gastric emptying. Tirzepatide activates both the GLP-1 and GIP receptors. These effects can support weight loss and glucose control, but they can also lead some patients to eat far less than intended. Nausea, early fullness, vomiting, diarrhea, and food aversion may compound the problem.

Thiamine is water-soluble and the body has limited storage capacity. A person who eats very little for an extended period, especially while vomiting, can become deficient more quickly than someone consuming a varied diet. Risk may be higher when there are additional factors such as a history of bariatric surgery, alcohol-use disorder, severe gastrointestinal disease, eating-disorder behavior, chronic malabsorption, or a very rapid reduction in food intake.

The key distinction is between a direct pharmacological effect and a treatment-associated nutritional cascade. Current evidence supports the possibility of the following cascade:

1. A GLP-1 medicine suppresses appetite or produces gastrointestinal symptoms.
2. The person eats substantially less or cannot retain food.
3. Thiamine intake and absorption fall while metabolic demand continues.
4. Neurological symptoms emerge as deficiency becomes severe.

This is a plausible mechanism, not proof that the medicine directly causes thiamine depletion in every user. A 2026 narrative review of micronutrient issues associated with GLP-1 therapy reported increasing concern about thiamine and other nutrient deficits over time, but it also emphasized that the clinical literature remains limited and that standardized monitoring data are lacking. The review is indexed in PubMed.

In other words, the risk is not best understood as “Ozempic destroys vitamin B1.” A more accurate description is that a medication that changes appetite and gastrointestinal function may contribute to severe nutritional deficiency in a susceptible person. That wording is less dramatic, but it matches the evidence more closely.

The 2026 tirzepatide case: why individual context matters

A 2026 case report in the British Journal of Diabetes described Wernicke encephalopathy following tirzepatide therapy in a 49-year-old woman with type 2 diabetes, autoimmune hepatitis, primary biliary cholangitis, iron-deficiency anemia, and a history of poor intake and vomiting. After a tirzepatide dose increase, she developed persistent vomiting and marked appetite suppression. She was hospitalized with vomiting and ketosis, then developed neurological symptoms.

The report included optic neuropathy among the clinical concerns. It is useful because it illustrates several overlapping risk factors rather than presenting a simple drug-versus-no-drug experiment. The patient had medical conditions that could affect nutrition and metabolism before the medication was introduced. The report therefore cannot prove that tirzepatide alone caused the neurological injury.

Its value is different. Case reports can show clinicians what a serious presentation looks like in the real world, especially when randomized trials are too small or too short to detect very rare complications. In this case, the combination of dose escalation, persistent vomiting, poor intake, ketosis, and neurological change created a pattern that should prompt urgent consideration of thiamine deficiency.

A separate 2026 case report described Korsakoff syndrome after rapid weight loss temporally associated with tirzepatide in a man with chronic alcohol-use disorder. That case again shows why individual vulnerability matters. Alcohol-use disorder is an established risk factor for thiamine deficiency, and rapid weight loss or reduced intake may add further stress. The report does not establish a population-level risk for all tirzepatide users.

These cases should not be converted into generalized predictions. They are clinical warning patterns: medication exposure plus prolonged vomiting, inadequate intake, rapid weight loss, and new neurological findings is a combination that deserves immediate evaluation.

Vitamin B1 deficiency versus NAION: two different vision questions

News coverage often compresses several separate findings into the phrase “GLP-1 vision loss.” That shorthand can confuse readers. Vitamin B1 deficiency and NAION are not interchangeable diagnoses.

The distinction is not academic. A person with sudden, painless loss of vision in one eye may have NAION, retinal disease, a vascular event, or another urgent eye disorder. A person with confusion, unsteady walking, double vision, and prolonged vomiting may have Wernicke encephalopathy. Both situations require urgent care, but they are investigated differently.

The earlier GLP-1 vision-loss evidence review at GLP1Place explains the initial separation between these pathways. The current update adds newer 2026 evidence and places greater emphasis on the nutritional mechanism and the limitations of the case-based data.

What the newer NAION studies show

NAION is a rare disorder involving the optic nerve. It typically presents as sudden, painless vision loss in one eye, often with a visual-field defect and impaired color vision. Risk factors include diabetes, hypertension, obstructive sleep apnea, hyperlipidemia, and an anatomical “disc at risk,” meaning a crowded optic-nerve head with little physiologic space.

A 2025 observational study of people with type 2 diabetes found that those prescribed semaglutide or tirzepatide had more NAION diagnoses during two years of follow-up than matched comparison patients. After matching, 35 patients in the GLP-1 group and 19 in the comparison group developed NAION. The hazard ratio was 1.76, but the absolute event frequency was low. Observational matching can reduce some differences between groups, but it cannot eliminate confounding from disease severity, health behavior, access to eye care, or other treatment differences. The study is available through PubMed.

Several 2026 meta-analyses reached related but not identical conclusions. One pooled analysis reported an association between GLP-1 receptor agonist use and NAION, while another found that the overall evidence remained heterogeneous and observational. A May 2026 systematic review covering more than 1.4 million patients reported substantial statistical heterogeneity across studies. High heterogeneity means the estimates varied considerably depending on the population, comparator, outcome definition, and study design.

Randomized clinical trials have not been designed primarily to detect NAION. The event is too rare for most trials to provide precise estimates, and ophthalmic outcomes may not be assessed uniformly. A 2026 pooled safety analysis of placebo-controlled liraglutide and semaglutide trials therefore provides useful context but cannot answer every question raised by postmarketing studies.

Regulators have responded cautiously. The United Kingdom’s Medicines and Healthcare products Regulatory Agency stated that semaglutide may be very rarely associated with NAION and advised urgent assessment for sudden or rapidly worsening vision loss. Australia’s Therapeutic Goods Administration issued similar safety information in July 2026. These communications do not establish that vitamin B1 deficiency is the cause of NAION. They address a separate optic-nerve signal.

What “millions of users” changes—and what it does not

Large numbers of people now receive GLP-1 medicines for diabetes, obesity, cardiovascular risk reduction, or related indications. Wider use means that extremely uncommon events will appear among treated patients even when the medicine is not the sole cause. It also makes postmarketing surveillance more valuable because clinical trials may enroll only a small fraction of the eventual treatment population.

At the same time, a rare event can become highly visible when a medicine is used by millions of people. A handful of cases may generate news coverage, lawsuits, social-media discussion, and additional reporting. That attention can help identify a real safety problem, but it can also make the risk appear more common than it is.

For vitamin B1 deficiency, the available evidence does not support a blanket claim that all users need routine high-dose supplementation or that every person on a GLP-1 medicine is at risk of blindness. The existing studies do support a more targeted awareness strategy: clinicians and patients should recognize when appetite suppression or gastrointestinal symptoms have progressed to prolonged nutritional compromise.

The same principle applies to retatrutide. Retatrutide is an investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. It is not yet supported by the same postmarketing experience as approved semaglutide or tirzepatide products. As clinical development expands, researchers should monitor vomiting, food intake, rapid weight loss, thiamine status, neurological symptoms, and ophthalmic outcomes rather than assuming that all incretin-based compounds have identical safety profiles.

Warning signs that should not be ignored

Readers should not attempt to diagnose Wernicke encephalopathy, nutritional optic neuropathy, NAION, diabetic retinopathy, or another eye disorder from an online article. The practical point is to recognize symptom combinations that warrant prompt medical attention.

• Sudden or rapidly worsening vision loss: especially when it is painless, affects one eye, or occurs with a new visual-field defect.
• Persistent vomiting: particularly when fluids or food cannot be kept down.
• Severe appetite suppression: when daily intake becomes unusually small or entire food groups disappear for prolonged periods.
• New confusion or extreme sleepiness: especially after days or weeks of poor intake.
• Unsteady walking or unexplained falls: a possible neurological warning sign.
• Double vision, abnormal eye movements, or new difficulty focusing: symptoms that can occur in Wernicke encephalopathy and other urgent conditions.
• Rapid weight loss accompanied by weakness or neurological change: a reason to contact a clinician promptly rather than simply continuing the treatment plan.

These symptoms do not prove vitamin B1 deficiency or a medication reaction. They may reflect dehydration, electrolyte abnormalities, diabetic emergencies, retinal disease, stroke, infection, or other conditions. The urgency comes from the possibility of preventable permanent injury.

How clinicians and researchers should interpret the evidence

The current evidence has three layers. The first is mechanistic plausibility: appetite suppression, vomiting, reduced intake, and rapid weight loss can produce nutritional deficiencies, and thiamine deficiency is a recognized cause of Wernicke encephalopathy. The second is case-based evidence. Published reports show that the syndrome has occurred in people taking semaglutide or tirzepatide, often in the presence of severe gastrointestinal or nutritional stress. The third is pharmacovigilance. The 15-case study found disproportionate reporting compared with other medicines.

Those layers are meaningful, but they do not equal a randomized causal estimate. There is no reliable denominator in the spontaneous reports. The cases may include incomplete laboratory information. Some patients had pre-existing conditions that independently increase the risk of malnutrition or neurological disease. The exact contribution of the medicine, the underlying disease, weight loss itself, and other exposures cannot be separated in every report.

Future research should move beyond simply counting adverse-event reports. Useful studies would measure dietary intake, vomiting duration, weight-loss velocity, thiamine biomarkers, alcohol exposure, bariatric-surgery history, kidney and liver function, and baseline neurological status. They should distinguish Wernicke encephalopathy, nutritional optic neuropathy, diabetic retinopathy, retinal vascular disease, and NAION rather than grouping all visual outcomes together.

Randomized trials may remain underpowered for rare events, so large linked databases and prospective registries will probably be important. Researchers should also report whether events occur during dose escalation, after treatment interruptions, or during periods of unusually rapid weight loss. Those details could identify which patients are most vulnerable without overstating risk for the broader treatment population.

Regulatory and compliance notes

Approved GLP-1 medicines have labeled indications, manufacturing controls, and postmarketing surveillance systems. That does not eliminate risk, but it provides a structured way to investigate adverse events. Unapproved or inaccurately labeled products create additional uncertainty because the actual ingredient, concentration, sterility, impurities, and dose may not match the label.

The FDA continues to warn about unapproved versions of semaglutide and tirzepatide used for weight loss. Product-quality problems can complicate interpretation of an adverse event because the patient may not have received the stated medicine or amount. For that reason, safety analyses should identify whether an event followed an approved product, a compounded preparation, or an unknown source. This article does not provide sourcing or acquisition guidance.

Researchers and clinicians should also avoid using the phrase “GLP-1 blindness” as if it were a single established adverse effect. Accurate terminology matters. A report of sudden vision loss may concern NAION. A report of abnormal eye movements during severe malnutrition may concern Wernicke encephalopathy. A patient with diabetes may have retinopathy or another vascular complication. Collapsing these conditions into one headline makes informed risk assessment harder.

For broader context on emerging safety signals, see GLP1Place’s 2026 GLP-1 safety study review. It explains why database associations require careful interpretation and why a signal is not the same as a confirmed adverse effect.

Researcher takeaways

1. The vitamin B1 question is plausible but rare. The best-supported pathway involves severe nutritional depletion associated with vomiting, appetite loss, rapid weight loss, or malnutrition.
2. The 2026 evidence is stronger than isolated anecdotes but still cannot establish incidence. Fifteen pharmacovigilance cases and six semaglutide case reports justify vigilance, not a population-wide prediction.
3. Vision loss has multiple possible causes. Wernicke encephalopathy, nutritional optic neuropathy, NAION, diabetic retinopathy, retinal vascular disease, and stroke should not be treated as one condition.
4. NAION is a separate emerging safety issue. The strongest current association involves semaglutide in some observational studies, while absolute event rates remain low and estimates vary.
5. Retatrutide evidence is immature. As an investigational medicine, it lacks the same real-world safety history as approved products.
6. Urgent symptoms matter more than online speculation. Sudden vision loss, confusion, abnormal eye movements, severe imbalance, or persistent vomiting requires prompt clinical evaluation.

Frequently asked questions

Can GLP-1 drugs cause vitamin B1 deficiency?

There is no strong evidence that semaglutide, tirzepatide, or other GLP-1 medicines directly destroy vitamin B1. However, appetite suppression, persistent vomiting, very low food intake, rapid weight loss, and malnutrition may create conditions in which thiamine stores become depleted.

Can vitamin B1 deficiency cause vision loss?

Severe thiamine deficiency can cause Wernicke encephalopathy with abnormal eye movements and, in uncommon cases, optic-nerve injury or visual loss. The injury can become permanent if treatment is delayed. This is different from NAION, another rare cause of sudden vision loss being studied in GLP-1 users.

What did the 2026 GLP-1 Wernicke study find?

A 2026 pharmacovigilance study and literature review identified 15 reported cases of Wernicke encephalopathy associated with GLP-1 receptor agonist treatment. Eight involved semaglutide and six involved tirzepatide. Thirteen patients had vomiting, appetite loss, rapid weight loss, or malnutrition. The reports show a safety signal, not proof of drug causation or an incidence rate.

Is sudden vision loss from Ozempic the same as vitamin B1 deficiency?

Not necessarily. Sudden, painless vision loss in one eye is a typical presentation of NAION, a rare optic-nerve disorder. Vitamin B1 deficiency more often appears with neurological symptoms such as confusion, unsteady walking, double vision, abnormal eye movements, or severe nutritional depletion. Only urgent clinical evaluation can distinguish the causes.

Which GLP-1 drugs are involved in the evidence?

Reports and studies have involved semaglutide products such as Ozempic, Wegovy, and Rybelsus, as well as tirzepatide products such as Mounjaro and Zepbound. Broader evidence also includes liraglutide, dulaglutide, and exenatide. Retatrutide remains investigational, so direct evidence about its vitamin B1 or vision risk is limited.

What symptoms should prompt urgent medical attention?

Sudden or rapidly worsening vision loss, new double vision, confusion, unusual sleepiness, severe imbalance, inability to walk normally, persistent vomiting, or inability to keep food and fluids down should receive urgent medical assessment. These symptoms can have many causes, and delaying evaluation may allow neurological or eye injury to become permanent.

Bottom line

The strongest 2026 evidence does not show that GLP-1 medicines routinely cause blindness. It identifies two separate safety questions that deserve careful attention. First, severe vomiting, inadequate intake, rapid weight loss, and malnutrition may contribute to vitamin B1 depletion and Wernicke encephalopathy in vulnerable patients. Second, rare optic-nerve disorders such as NAION are being investigated, with the clearest regulatory concern currently focused on semaglutide.

The practical message is not to stop a prescribed medicine based on a headline or to self-treat a suspected deficiency. It is to treat persistent vomiting, inability to eat, neurological symptoms, and sudden vision changes as medical issues requiring timely evaluation. In rare nutritional emergencies, early recognition can make the difference between recovery and permanent neurological injury.